Path Ex

Path Ex is pioneering a direct, device-based approach to treating sepsis by physically removing pathogens from the blood. Its CycloPE® device is designed for rapid, broad-spectrum bacterial clearance and integrates with existing ICU systems. Founded in 2017 and now based in San Francisco, the company has secured non-dilutive grant funding, completed early clinical studies, and holds FDA Breakthrough Device status as it progresses toward pivotal trials and potential commercialization. The technology addresses a critical unmet need in a high-mortality condition where current antibiotic therapies are increasingly challenged by resistance.

Proprietary extracorporeal blood purification platform designed for selective, broad-spectrum capture and removal of bacteria from circulating blood, integrating with standard ICU systems.

Competition includes other blood purification devices like CytoSorb (cytokine adsorption) and oXiris (cytokine and endotoxin adsorption), which target inflammatory mediators rather than pathogens directly. Novel antibiotic therapies and immunomodulators are also in development. Path Ex's key differentiation is the direct, mechanical removal of the causative bacteria, a first-in-class approach aiming for source control.